CorrespondenceAssociation between KRAS rs61764370 and triple-negative breast cancer—a false positive? – Authors' reply
Reference (1)
Cited by (2)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
2016, Gynecologic OncologyCitation Excerpt :However, in a subsequent study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has been questioned given the very small sample sizes and the number of subgroups tested [16,17]. Another report found no association with sporadic or familial breast cancer risk (695 combined cases, 270 controls), but found that the variant was associated with ERBB2-positive and high grade disease, based on 153 cases who used post-menopausal hormone replacement therapy [18].
Copyright © 2011 Elsevier Ltd. All rights reserved.